131 related articles for article (PubMed ID: 35500848)
1. Evaluation of factors influencing the ratio of the trough blood concentration to dose level of everolimus in Japanese kidney transplant recipients.
Geka Y; Hamada Y; Fuchinoue S; Kimura T
Transpl Immunol; 2022 Aug; 73():101609. PubMed ID: 35500848
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
4. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
5. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.
Shao ZY; Yan LN; Wang WT; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2012 Mar; 18(9):991-8. PubMed ID: 22408361
[TBL] [Abstract][Full Text] [Related]
7. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
[TBL] [Abstract][Full Text] [Related]
8. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
10. Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation.
Sumethkul V; Tankee P; Worawichawong S; Jirasiritham S
Transplant Proc; 2017 Oct; 49(8):1743-1746. PubMed ID: 28923619
[TBL] [Abstract][Full Text] [Related]
11. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M
Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
[TBL] [Abstract][Full Text] [Related]
13. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
Sessa A; Esposito A; Giliberti A; Iavicoli G; Costa C; Bergallo M; Lettieri E; Rossano R; Capuano M
Transplant Proc; 2009 May; 41(4):1178-82. PubMed ID: 19460510
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
Ayar Y; Ersoy A; Ocakoglu G; Yildiz A; Oruc A; Soyak H; Calapkulu M; Sahin AB; Topal NB; Okeer E; Coskun B; Kaygisiz O; Kordan Y; Vuruskan H
Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
[TBL] [Abstract][Full Text] [Related]
16. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
17. Interstitial Lung Disease After Kidney Transplantation and the Role of Everolimus.
Solazzo A; Botta C; Nava F; Baisi A; Bonucchi D; Cappelli G
Transplant Proc; 2016 Mar; 48(2):349-51. PubMed ID: 27109953
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
19. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
Pascual J
Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]